Consensus EPS · Q2 2026
$4.75
Consensus revenue · Q2 2026
$3.2B
Analysts
14
Expected report
Aug 3, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 14 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $3.1B | $3.2B | $3.3B |
| EPS | $4.26 | $4.75 | $5.17 |
| EBITDA | $1.1B | $1.2B | $1.2B |
| EBIT | $1.1B | $1.1B | $1.1B |
| Net income | $1.1B | $1.2B | $1.3B |
- Revenue$3.2B
- EPS$4.75
- EBITDA$1.2B
- EBIT$1.1B
- Net income$1.2B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $3B | $3B | -0.2% | $4.47 | $4.24 | +5.4% |
| Q4 2025 | $3.2B | $3.2B | +1.4% | $5.03 | $5.11 | -1.6% |
- Q1 2026-0.2%+5.4%
- Q4 2025+1.4%-1.6%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Vertex Pharmaceuticals (VRTX) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 4 analysts.
- Low
- $350.00
- Consensus
- $547.93
- Median
- $572.00
- High
- $616.00
- Current
- $472.57
- Upside
- +15.9%
Upside calculated vs most recent trading price of $472.57.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 56 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 13, 2026 | UBS | maintain | Buy | Buy |
| Jul 13, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 7, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jul 7, 2026 | Baird | maintain | Underperform | Underperform |
| May 6, 2026 | Barclays | maintain | Overweight | Overweight |
| May 5, 2026 | RBC Capital | maintain | Outperform | Outperform |
| May 5, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| May 5, 2026 | Canaccord Genuity | maintain | Hold | Hold |
| May 5, 2026 | Bernstein | maintain | Outperform | Outperform |
| Apr 30, 2026 | Canaccord Genuity | maintain | Hold | Hold |
- Jul 13, 2026UBSBuy
- Jul 13, 2026Truist SecuritiesBuy
- Jul 7, 2026RBC CapitalOutperform
- Jul 7, 2026BairdUnderperform
- May 6, 2026BarclaysOverweight
- May 5, 2026RBC CapitalOutperform
- May 5, 2026Morgan StanleyOverweight
- May 5, 2026Canaccord GenuityHold
- May 5, 2026BernsteinOutperform
- Apr 30, 2026Canaccord GenuityHold
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.